According to a recent LinkedIn post from Newronika, the company is participating in the 3rd Expert Summit on the Future of Deep Brain Stimulation in Würzburg, Germany. The post highlights that members of Newronika’s Scientific Advisory Board are featured in a dedicated debate session on how to optimize deep brain stimulation in the time domain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post lists several discussion topics, including comparisons between adaptive DBS and open-loop patterned stimulation, and between pathological signal suppression and physiological enhancement. It also references a session on whether autotuning based on biomarkers could replace the neurologist, and another on the role of adaptive DBS in improving freezing of gait.
The post further notes that attendees can visit Newronika’s booth to learn about its alphaDBS system and its role in adaptive neurostimulation. For investors, this visibility at a specialized DBS summit suggests an effort to position alphaDBS as a clinically relevant, next-generation solution in neuromodulation and Parkinson’s disease management.
This type of expert-focused engagement may support Newronika’s credibility among key opinion leaders, which is often important for adoption of advanced medical devices. If the underlying clinical and technical claims of adaptive DBS prove out in practice, the company could strengthen its competitive position in the MedTech and neuromodulation markets, potentially supporting future commercial and partnership opportunities.